Product Description: Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC)[1].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Andrea Necchi, et al. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology 2019 37:7_suppl, 409-409.
CAS Number: 1312305-12-6
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: FGFR